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EDITORIAL COMMENT
Dead Is Dead, but Can We
Identify Patients at Increased
Risk for Sudden Cardiac Death?*
Arthur J. Moss, MD, FACC
Rochester, New York
The paper by Huikuri et al. (1) in this issue of the Journal
takes on special relevance in view of the recent demonstra-
tion that the implanted cardioverter defibrillator (ICD)
improves survival in high-risk patients with chronic coro-
nary heart disease (2,3). The question, simply put, is
whether data from clinical and noninvasive cardiac tests
collected during an acute myocardial infarction (AMI) can
identify a subset of patients who are specifically at high risk
for sudden cardiac death (SCD) in the post-hospital period
during long-term follow-up. It is already well-known that
the mortality risk in post-infarction patients is inversely
related to the left ventricular ejection fraction (4) and that
SCD makes up roughly 50% of cardiac mortality (5),
although the percentage varies widely in reported studies
(6). Thus, are there risk stratifiers that can accurately
identify patients at high risk for SCD?
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Huikuri et al. (1) have attempted to answer this question
by studying a consecutive series of 675 post-infarction
patients who were enrolled during a 2.5-year period begin-
ning in 1996 and followed after hospital discharge for an
extended period of time. Several clinical and state-of-the-art
noninvasive cardiac tests were obtained on these patients
before hospital discharge, and the findings from these tests
were related to sudden and non-SCD during follow-up that
averaged almost four years. The patients were optimally
treated with beta-blockers, with 95% of the patients receiv-
ing beta-blockers two years after hospital discharge. Clas-
sification of sudden and non-SCD utilized standard clinical
criteria, with two end point committees categorizing the
mode of death. The total mortality during a mean follow-up
of 43 months was 15%, with 8.7% (54 patients) classified as
cardiac death—37 categorized as non-SCD and 17 as SCD.
The relatively small number of cardiac deaths during the
extended follow-up may explain, in part, the limited power
of the study to identify patients at risk for SCD in this
study. Only ejection fraction 0.40, nonsustained ventric-
ular tachycardia on Holter recording, and a positive signal-
averaged electrocardiogram entered a multivariate Cox
model with hazard ratios significantly 1.0 for differenti-
ating SCD from survival. However, the positive predictive
accuracy of each of these three risk factors was 15%, and
these findings indicate the clinical uselessness of these
parameters for predicting patients who are likely to die of
SCD.
Several studies, including the one by Huikuri et al. (1),
have evaluated various clinical and non-invasive electro-
physiologic markers for cardiac death, but none of these
markers discriminated between sudden and non-SCD.
Heart rate variability, baroreceptor sensitivity, QT-dispersion,
QRS-interval duration, and the signal-averaged electrocar-
diogram all fall into this category. Huikuri et al. (1) suggest
that their inability to predict SCD is due to the excellent
adherence of their study patients to beta-blocker therapy,
because beta-blockers have been shown to prevent SCD.
They also note an unexpectedly low frequency of SCD in
the first year after hospital discharge following the index
myocardial infarction. But other reasons for limited findings
may be operative. Currently, patients are being hospitalized
with smaller-sized myocardial infarctions as a result of more
sensitive enzyme markers for myocardial necrosis. The
cardiac damage caused by AMIs is being attenuated by early
thrombolysis and aggressive acute coronary revascularization
procedures. The net result is that patients are being dis-
charged from the hospital with better left ventricular func-
tion in the “beta-blocking era” than in the past, with many
factors other than beta-blockers that could account for the
improved outcome. In brief, the landscape of acute coronary
disease has changed dramatically in the past decade with
resultant improvement in the clinical course of patients after
discharge from the hospital. The post-infarction mortality
rate has declined during the past decade, but has this decline
resulted in a shift from sudden death to non-sudden death?
That is a question that cannot be answered by any of the
recent studies.
Mortality is an end point that is unequivocal, for dead is
dead (7). Categorization of the mechanism of cardiac death,
especially when death occurs out-of-hospital, is imprecise
for it is based on retrospective clinical data involving the
circumstances and the location of death, pre-morbid clinical
symptomatology that is often difficult to ascertain after the
fatal event, and the time course of the terminal event. The
error rate associated with the subclassification of cardiac
death into sudden and non-SCD may be quite large,
whether autopsy findings are available or not. Analyses by
the Multicenter Automatic Defibrillator Implantation Trial
(MADIT-II) End-point Review Committee using the
Hinkle-Thaler mortality classification system (8) are shed-
ding some light on this topic (H. Greenberg, personal
communication, 2003). Sudden cardiac death accounted for
62% of the cardiac deaths in the conventionally treated
MADIT-II patients, and 35% in the ICD group. The
reduction in mortality with the ICD was almost exclusively
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the result of a decrease in cardiac death categorized as SCD.
Using various assumptions about the efficacy of the ICD in
preventing sudden death in MADIT-II, it appears that the
imprecision, that is, the misclassification rate, in categoriz-
ing death as sudden due to suspected ventricular tachycar-
dia/fibrillation may be an overclassification in the range of
20% to 30%.
Is our failure to identify patients at risk for SCD due to
the lower post-infarction cardiac mortality in the current
therapeutic era, the non-specificity of the presently available
non-invasive electrophysiologic tests, and the potential error
rate in accurate classification of the end point SCD? In part,
yes, but I don’t think these issues are the complete answer.
It was previously thought that induction of ventricular
tachycardia or fibrillation during invasive electrophysiologic
(EP) testing would identify patients at subsequent risk for
SCD. A recent prospective study showed that coronary
patients who were non-inducible at EP testing had essen-
tially the same risk for sudden death as those who were
inducible (9). Preliminary findings from MADIT-II indi-
cate that ICD-treated patients who were non-inducible at
EP testing at the time of ICD implantation had more
appropriate ICD shocks for ventricular fibrillation during
their subsequent clinical course than patients who were
inducible at EP testing. Thus, our current array of non-
invasive and invasive tests performed during the hospital
phase of AMI are inadequate to specifically identify who is
at increased risk of dying from sudden rather than non-
sudden death during follow-up time after an index coronary
event.
What determines the development of malignant ventric-
ular arrhythmias in patients with coronary heart disease, and
can we identify those at increased risk for fatal arrhythmias?
The evidence is accumulating that the occurrence of an
abrupt ventricular arrhythmia is a multifactorial, time-
dependent process involving a changing complex interplay
of myocardial scar, ischemia, adrenergic factors, electrical
heterogeneity, time, and possibly genetic factors, all super-
imposed on a vulnerable myocardial substrate that is “ac-
quired” as a result of occlusive and progressive coronary
artery disease. This multifactorial process has considerable
overlap with factors that contribute to progressive heart
failure. We are most likely dealing with a probabilistic event
in which each of the currently measured risk factors iden-
tifies only a small fraction of the multifactorial risk process.
Clearly, more specific physiologically based tests, better
mathematical modeling involving the time-dependent pro-
cess, and greater precision in determining when sudden
death is really sudden are needed to identify patients at
increased risk for sudden death. At present, it is probably
best to use an ejection fraction 0.30 or 0.35 to predict
coronary patients at risk for both sudden and non-SCD and
simply assume that SCD accounts for approximately 50% of
all cardiac deaths.
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